摘要
肿瘤微环境(TME)是各种细胞的驻留者,它们致力于肿瘤的异质群体。 TME 建立了一个通信网络,用于肿瘤细胞、基质和其他间质细胞之间的串扰和信号传递。交叉通讯驱动 TME 细胞的重编程,从而通过多种信号通路促进癌症进展和转移。最近,TME 衍生的外泌体被认为是 TME 细胞重编程的关键传播者。这篇综述探讨了 TME 衍生的外泌体在基质调节中的作用,包括重新编程基质细胞、ECM 和肿瘤细胞代谢,以及肿瘤转化。随后,我们描述了外泌体在转移前生态位发育、干性和肿瘤血管系统的维持以及耐药性发展中的作用。我们还精确探索了肿瘤衍生的外泌体,包括诊断、药物递送和疫苗开发。我们讨论了目前已建立的生物工程外泌体作为化疗药物、RNAi 分子和天然化合物的载体。最后,我们提出了用于量化肿瘤衍生外泌体的四跨膜蛋白和基于 DNA 的精确方法。总体而言,TME 衍生的外泌体介导的 TME 重编程和精准策略可以阐明靶向治疗干预的潜在机制。
关键词: 血管生成、癌症干细胞、外泌体、转移、肿瘤微环境、信号通路。
Current Medicinal Chemistry
Title:Exosomes: Critical Mediators of Tumour Microenvironment Reprogramming
Volume: 28 Issue: 39
关键词: 血管生成、癌症干细胞、外泌体、转移、肿瘤微环境、信号通路。
摘要: Tumour microenvironment (TME) is a resident of a variety of cells, which are devoted to the heterogeneous population of the tumour. TME establishes a communication network for crosstalk and signalling between tumour cells, stroma, and other interstitial cells. The cross-communication drives the reprogramming of TME cells, which promote cancer progression and metastasis via diverse signalling pathways. Recently, TMEderived exosomes are recognized as critical communicators of TME cell reprogramming. This review addresses the role of TME-derived exosomes in the modulation of stroma, including reprogramming the stromal cells, ECM and tumour cell metabolism, as well as neoplastic transformation. Subsequently, we described the role of exosomes in pre-metastatic niche development, maintenance of stemness and tumour vasculature, as well as development of drug resistance. We also explored tumour-derived exosomes in precision, including diagnosis, drug delivery, and vaccine development. We discussed the currently established bioengineered exosomes as carriers for chemotherapeutic drugs, RNAi molecules, and natural compounds. Finally, we presented tetraspanin and DNA-based precision methods for the quantification of tumour-derived exosomes. Overall, TMEderived exosome-mediated reprogramming of TME and precision strategies could illuminate the potential mechanisms for targeted therapeutic intervention.
Export Options
About this article
Cite this article as:
Exosomes: Critical Mediators of Tumour Microenvironment Reprogramming, Current Medicinal Chemistry 2021; 28 (39) . https://dx.doi.org/10.2174/0929867328666201217105529
DOI https://dx.doi.org/10.2174/0929867328666201217105529 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Novel Treatment Strategy for Sepsis and Septic Shock Based on the Interactions between Prostanoids, Nitric Oxide, and 20-Hydroxyeicosatetraenoic Acid
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Molecular Sieves in Medicine
Mini-Reviews in Medicinal Chemistry Therapeutic Potential of Melatonin in the Regulation of MiR-148a-3p and Angiogenic Factors in Breast Cancer
MicroRNA Studying the Human Gut Microbiota in the Trans-Omics Era - Focus on Metagenomics and Metabonomics
Current Pharmaceutical Design MicroRNA-Mediated Cancer Metastasis Regulation via Heterotypic Signals in the Microenvironment
Current Pharmaceutical Biotechnology Identification of Marker Genes for Cancer Based on Microarrays Using a Computational Biology Approach
Current Bioinformatics Wnt / β-Catenin Signaling Pathway as Novel Cancer Drug Targets
Current Cancer Drug Targets Indolo[2,3-a]quinolizidines and Derivatives: Bioactivity and Asymmetric Synthesis
Current Pharmaceutical Design Synthesis of Novel 2,3,4-trisubstituted-oxazolidine Derivatives and In Vitro Cytotoxic Evaluation
Medicinal Chemistry Molecular Chaperone ORP150 in ER Stress–related Diseases
Current Pharmaceutical Design Small Molecule Inhibitors of Multidrug Resistance Gene (MDR1) Expression: Preclinical Evaluation and Mechanisms of Action
Current Cancer Drug Targets The Biology of Cholecystokinin and Gastrin Peptides
Current Topics in Medicinal Chemistry Genomic and Epigenomic Instability, Fragile Sites, Schizophrenia and Autism
Current Genomics Mammalian DNA (Cytosine-5) Methyltransferase Mechanisms and RNA-Mediated Inhibition for Future Therapies
Epigenetic Diagnosis & Therapy (Discontinued) Network of WNT and Other Regulatory Signaling Cascades in Pluripotent Stem Cells and Cancer Stem Cells
Current Pharmaceutical Biotechnology Design and Synthesis of Quinazolinone Derivatives as Anti-inflammatory Agents: Pharmacophore Modeling and 3D QSAR Studies
Medicinal Chemistry 99mTc-HYNIC-D4 Peptide: A New Small Radiolabeled Peptide for Non Small Cell Lung Tumor Targeting
Anti-Cancer Agents in Medicinal Chemistry Anticancer Drug-Induced Immunomodulation and Cancer Therapeutics
Current Cancer Therapy Reviews Effects of PPARγ Ligands on Vascular Tone
Current Molecular Pharmacology Isolation of a New Trypsin Inhibitor from the Faba Bean (Vicia faba cv. Giza 843) with Potential Medicinal Applications
Protein & Peptide Letters